Literature DB >> 17555796

Glutathione S-transferase: differential expression of alpha, mu, and pi isoenzymes in benign prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma.

David G Bostwick1, Isabelle Meiers, Jonathan H Shanks.   

Abstract

Glutathione S-transferases (GST) comprise a family of enzymes which are critical for inactivation of toxins and carcinogens. We examined the cellular expression of multiple subclasses of GST immunohistochemically in 25 radical prostatectomy specimens with clinically localized prostate cancer. Gleason scores ranged from 5 to 9, and pathologic stages varied from pT2a to pT3b (all N0M0). Antibodies were directed against GST Ya, Yc, and Yk (alpha subclass), Yb1 (micro subclass), and YPr (pi subclass). The percentage of positive cells and intensity of staining was assessed for benign epithelium, high-grade prostatic intraepithelial neoplasia (PIN), and adenocarcinoma. GSTalpha (Ya) was detected in 30% of cells (mean) in benign acini, 4.9% of cells in high-grade PIN, and 4.5% of cells in adenocarcinoma. The corresponding results for alpha (Yk), micro (Yb1), and pi (Yp) were 12.7%, 10.9%, and 3.5%; 8.7%, 5.2%, and 0.6%; and 66.7,% 0%, and 0%, respectively. GST Yc (alpha subclass) displayed the lowest level of expression, with diffuse weak staining in scattered benign secretory cells and only single cells (<1%) in high-grade PIN and carcinoma. These results demonstrate consistent reduction or loss of expression of all subclasses of GST with progression of prostatic neoplasia from benign epithelium to high-grade PIN and carcinoma. We hypothesize that carcinogenesis in the prostate results from impaired cellular handling of mutagenic agents owing to reduction or loss of expression of multiple GST and other detoxifying and antimutagenesis agents.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17555796     DOI: 10.1016/j.humpath.2007.02.008

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  20 in total

Review 1.  Gleason 6 Prostate Cancer: Translating Biology into Population Health.

Authors:  Scott E Eggener; Ketan Badani; Daniel A Barocas; Glen W Barrisford; Jed-Sian Cheng; Arnold I Chin; Anthony Corcoran; Jonathan I Epstein; Arvin K George; Gopal N Gupta; Matthew H Hayn; Eric C Kauffman; Brian Lane; Michael A Liss; Moben Mirza; Todd M Morgan; Kelvin Moses; Kenneth G Nepple; Mark A Preston; Soroush Rais-Bahrami; Matthew J Resnick; M Minhaj Siddiqui; Jonathan Silberstein; Eric A Singer; Geoffrey A Sonn; Preston Sprenkle; Kelly L Stratton; Jennifer Taylor; Jeffrey Tomaszewski; Matt Tollefson; Andrew Vickers; Wesley M White; William T Lowrance
Journal:  J Urol       Date:  2015-04-04       Impact factor: 7.450

2.  Epigenetic DNA methylation of antioxidative stress regulator NRF2 in human prostate cancer.

Authors:  Tin Oo Khor; Francisco Fuentes; Limin Shu; Ximena Paredes-Gonzalez; Anne Yuqing Yang; Yue Liu; Dominic J Smiraglia; Srinivasan Yegnasubramanian; William G Nelson; Ah-Ng Tony Kong
Journal:  Cancer Prev Res (Phila)       Date:  2014-09-29

3.  A NADPH oxidase-dependent redox signaling pathway mediates the selective radiosensitization effect of parthenolide in prostate cancer cells.

Authors:  Yulan Sun; Daret K St Clair; Yong Xu; Peter A Crooks; William H St Clair
Journal:  Cancer Res       Date:  2010-03-16       Impact factor: 12.701

4.  shRNA-mediated GSTP1 gene silencing enhances androgen-independent cell line DU145 chemosensitivity.

Authors:  Peng Jin; Jinliang Xie; Xiangrong Zhu; Cheng Zhou; Xiang Ding; Luoyan Yang
Journal:  Int Urol Nephrol       Date:  2013-12-11       Impact factor: 2.370

Review 5.  Redox-mediated and ionizing-radiation-induced inflammatory mediators in prostate cancer development and treatment.

Authors:  Lu Miao; Aaron K Holley; Yanming Zhao; William H St Clair; Daret K St Clair
Journal:  Antioxid Redox Signal       Date:  2014-01-22       Impact factor: 8.401

6.  Quantitative proteomic profiling of prostate cancer reveals a role for miR-128 in prostate cancer.

Authors:  Amjad P Khan; Laila M Poisson; Vadiraja B Bhat; Damian Fermin; Rong Zhao; Shanker Kalyana-Sundaram; George Michailidis; Alexey I Nesvizhskii; Gilbert S Omenn; Arul M Chinnaiyan; Arun Sreekumar
Journal:  Mol Cell Proteomics       Date:  2009-11-09       Impact factor: 5.911

7.  Expression level and DNA methylation status of glutathione-S-transferase genes in normal murine prostate and TRAMP tumors.

Authors:  Cory K Mavis; Shannon R Morey Kinney; Barbara A Foster; Adam R Karpf
Journal:  Prostate       Date:  2009-09-01       Impact factor: 4.104

8.  Expression patterns of carcinogen detoxifying genes (CYP1A1, GSTP1 & GSTT1) in HNC patients.

Authors:  Nosheen Masood; Mahmood Akhtar Kayani
Journal:  Pathol Oncol Res       Date:  2012-08-25       Impact factor: 3.201

9.  Disruption of PPARgamma signaling results in mouse prostatic intraepithelial neoplasia involving active autophagy.

Authors:  M Jiang; S Fernandez; W G Jerome; Y He; X Yu; H Cai; B Boone; Y Yi; M A Magnuson; P Roy-Burman; R J Matusik; S B Shappell; S W Hayward
Journal:  Cell Death Differ       Date:  2009-10-16       Impact factor: 15.828

10.  Nrf2 expression is regulated by epigenetic mechanisms in prostate cancer of TRAMP mice.

Authors:  Siwang Yu; Tin Oo Khor; Ka-Lung Cheung; Wenge Li; Tien-Yuan Wu; Ying Huang; Barbara A Foster; Yuet Wai Kan; Ah-Ng Kong
Journal:  PLoS One       Date:  2010-01-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.